Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has received requests from five promoter group members to reclassify from the 'Promoter Group' category to the 'Public' category under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The requests are subject to consideration and approval by the Board of Directors and other applicable conditions.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange about the transcript of the conference call held on August 12, 2026, for the unaudited financial results for the quarter ended June 30, 2026.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange about General Updates related to the buyback of equity shares using the open market purchase through Stock Exchanges. The company has certified compliance with SEBI regulations and will maintain compliance during the buyback process.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange about the link of recording of the conference call for the unaudited financial results for the quarter ended June 30, 2026, which is available on the company's website.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has submitted the Exchange the Board Resolution of Buyback, approving the buyback of up to 10% of the paid-up capital and free reserves of the Company through the open market route.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has announced a buyback of its equity shares from the open market through stock exchanges under the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended. The buyback will open on August 14, 2026, and will end on the earlier of November 20, 2026, or when the company completes the buyback by deploying the amount equivalent to the Maximum Buyback Size.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange about Copy of Newspaper Publication regarding Extract of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange about Investor Presentation, enclosed is the Earnings Presentation for the quarter ended June 30, 2026. Revenue grew by 2% on y-o-y basis to ₹ 1,859 million in Q1 FY27 from ₹ 1,859 million in Q1 FY26. EBITDA de-grew by 10% to ₹ 510 million in Q1 FY27 from ₹ 632 million in Q4 FY26. PAT decreased to ₹ 386 million in Q1 FY27 from ₹ 453 million in Q4 FY26.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has announced its unaudited financial results for the first quarter ended June 2026, with revenue from operations growing by 2% year-on-year to ₹1,898 million and EBITDA margin standing at 27%. The company's profit after tax de-grew by 5% to ₹386 million, and earnings per share stood at ₹3.31.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has approved the buyback of up to 1,394,000 equity shares at a price not exceeding ₹500 per share, and the acquisition of the remaining 4.28% stake in its subsidiary JC Biotech Private Limited. The company has also approved the infusion of up to ₹20 million in its subsidiary Advanced Nutrazyme Private Limited.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2026. The Board has approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026. Additionally, the Board has approved the Buyback of fully paid-up equity shares having a face value of ? 2/- (Rupees Two only) each of the Company at a price not exceeding ? 500/- (Rupees Five Hundred only) per equity share. The Board has also approved the acquisition of the remaining stake of 4.28% Equity Shares from the other existing Shareholders of JC Biotech Private Limited and the infusion of additional funds not exceeding ? 20 million in Advanced Nutrazyme Private Limited.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has submitted its financial results for the quarter ended June 30, 2026, and approved a buyback of equity shares, acquisition of a remaining stake in JC Biotech Private Limited, and infusion of additional funds in Advanced Nutrazyme Private Limited.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has scheduled a conference call to discuss its un-audited financial results for the quarter ended June 30, 2026, on August 12, 2026.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange about the outcome of its 37th Annual General Meeting, where the members approved the re-appointment of the Whole Time Director, appointment of an Independent Director, and re-appointment of the Statutory Auditors.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has submitted the Scrutinizer's report and voting results of the 37th Annual General Meeting held on July 31, 2026, where all resolutions were passed with the requisite majority.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited held its 37th Annual General Meeting on July 31, 2026, through Video Conference. The meeting was attended by 106 members, and the required quorum was present. The company declared a final dividend of ₹ 1.35 per equity share for the financial year ended March 31, 2026. The meeting also approved the appointment of a director, reappointment of statutory auditors, and other resolutions.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming securities received for dematerialisation during the quarter ended June 30, 2026.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange about a copy of newspaper publication regarding the 37th Annual General Meeting (AGM) and Remote e-voting facility.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has informed the Exchange regarding the sending of a letter to shareholders who have not registered their email addresses with the Company/Registrar & Share Transfer Agent/Depositories, providing a web-link to access the Integrated Annual Report for FY 2025-26 and the Notice of 37th Annual General Meeting.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, as per the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.